医学
托珠单抗
类风湿性关节炎
生物标志物
关节炎
免疫学
内科学
C反应蛋白
抗体
胃肠病学
炎症
生物化学
化学
作者
Yusuke Takahashi,Minoru Fujimoto,Satoshi Serada,Atsushi Ogata,Toshihiro Nanki,Kimie Hattori,Tsutomu Takeuchi,Tetsuji Naka
标识
DOI:10.1136/annrheumdis-2015-eular.5386
摘要
Background
C-reactive protein (CRP) is frequently used to evaluate inflammation in patients with rheumatoid arthritis (RA). However, CRP is normalized when IL-6 function is potently suppressed by anti-cytokine biologics such as tocilizumab. Therefore, there is growing need for a new biomarker that can detect RA disease activity during this therapy. By proteomic screening of sera from patients with RA, we previously identified serum leucine-rich alpha-2 glycoprotein (LRG) as a potential biomarker that reflects disease activity in RA better than CRP. Objectives
The object of this study is to investigate the clinical significance of LRG as a biomarker of RA disease activity during anti-IL6 biologic therapy. Methods
As a preclinical testing, cynpmolgus monkeys with collagen induced arthritis (CIA) were treated with anti-IL-6 receptor antibody (anti-IL-6-R mAb) and joint sewelling and rigidity were scored for clinical assessment of arthritis throughout the experiment. At the time of sacrifice, blood samples were collected and serum LRG and CRP levels were evaluated. Results
In CIA monkeys with anti-IL-6R mAb treatment, plasma LRG levels correlated better with disease activity than plasma CRP levels, presumably due to the fact that LRG levels were elevated in some animals with negative CRP in spite of high arthritis scores. Furthermore, among tocilizumab-treated patients for 6months with normalized CRP levels, serum LRG levels were significantly higher in patients with active RA (defined by CDAI>2.8) than those with RA in remission (CDAI≤2.8). Conclusions
Our study indicates that LRG is more useful biomarker for discriminating active diseases in RA, even when CRP levels are reduced or normalized under IL-6 suppression. References
Navarro-Millán I, et al. Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor Receptor Clin Ther 2012; 788-802 Disclosure of Interest
None declared
科研通智能强力驱动
Strongly Powered by AbleSci AI